CHONGQING LUMMY PHARMACEUTICAL CO., LTD.

Chongqing Lummy Pharmaceutical Co., Ltd.

300006

CNE100000H10

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
2.91 ^CNY	-3.00%		-1.69%	-21.77%

23/04	Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/03	Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:300006) dropped from S&P Global BMI Index

June 20, 2022 at 09:30 am IST

Latest news about Chongqing Lummy Pharmaceutical Co., Ltd.

Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	23/04	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug	18/03	MT
Lummy Pharma Gets Nod to Market Nicorandil	04/03	MT
Lummy Pharmaceutical's Ramosetron Hydrochloride Injection Passes Regulatory Evaluation	10/11	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	20/23/20	CI
Lummy Pharmaceutical's Unit Gets Nod to Trial Ovarian Cancer Drug; Shares Surge 20%	15/23/15	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/23/23	CI
Chongqing Lummy Pharmaceutical's Cancer Drug Passes Regulatory Evaluation	07/23/07	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/23/21	CI
Chongqing Lummy Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding	16/23/16	CI
Lummy Pharma Unit Gets Regulatory Nod in China for Liver Cirrhosis Drug	02/23/02	MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:300006) dropped from S&P Global BMI Index	20/22/20	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Chengdu Xindu District Cundetang Pharmacy Co., Ltd. announced that it has received $7.800000 million in funding from KIP China, Chongqing Lummy Pharmaceutical Co., Ltd. and another investor.	26/21/26	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	28/21/28	CI
Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:300006) added to S&P Global BMI Index	20/21/20	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	30/21/30	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	23/21/23	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2020	22/21/22	CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	18/21/18	CI
Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. for approximately CNY 200 million.	12/21/12	CI

Chart Chongqing Lummy Pharmaceutical Co., Ltd.

Duration

Period

Chart Chongqing Lummy Pharmaceutical Co., Ltd.

More charts

Chongqing Lummy Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of medicines. The Companyâs medicines consist of anti-infection medicines, special medicines, infusion, Chinese patent drugs and herbal decoction pieces. The Company's main products include carbon nanoparticles suspension injection, omeprazole enteric capsules, mycobacterium phlei F.U.36 injection, levofloxacin hydrochloride and tranexamic acid and sodium chloride injection, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

02/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHONGQING LUMMY PHARMACEUTICAL CO., LTD.	-21.77%	425M
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+30.34%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	209B
ROCHE HOLDING AG	-6.83%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals